Evidence map›Paper›PMID 25249300›Full record

Trial reportJournal of the American Heart Association2014

A novel protein glycan biomarker and future cardiovascular disease events.

Akintunde O Akinkuolie, Julie E Buring, Paul M Ridker, Samia Mora

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000479 (Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women), which is not on this map. Cited by 131 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000479 phase3completednot on this map

Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women

TypeinterventionalSponsorBrigham and Women's HospitalRan1992 to 2005Enrolled39,876ConditionsCardiovascular Diseases, Cerebrovascular Disorders, Coronary Disease, Heart DiseasesArmsAspirin, Vitamin E, Placebo
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 2 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Trial
  18. Trial
  19. Trial
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Akintunde O AkinkuolieDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.O.A., J.E.B., P.R., S.M.).
Julie E BuringDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.O.A., J.E.B., P.R., S.M.).
Paul M RidkerDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.O.A., J.E.B., P.R., S.M.) Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.R., S.M.).
Samia MoraDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.O.A., J.E.B., P.R., S.M.) Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.R., S.M.).
Brigham and Women's Hospital · USHarvard University · US

Funding

Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
Training Program in the Epidemiology of CVDT32HL007575 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BURING, JULIE E., RIDKER, PAUL M. · 1985 to 2019
$5.0M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
The Phathophenotype Landscape of Complex DiseaseU01HL108630 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2011 to 2014
$2.7M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
NCI NIH HHS CA 47988NCI NIH HHS R01 CA047988NHLBI NIH HHS HL 080467NHLBI NIH HHS HL43851NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS T32 HL007575NHLBI NIH HHS U01 HL108630
6 · The paper itself

Abstract

backgroundGlycosylated proteins partake in multiple cellular processes including inflammation. We hypothesized that GlycA, a novel biomarker of protein glycan N-acetyl groups, is related to incident cardiovascular disease (CVD), and we compared it with high-sensitivity C-reactive protein (hsCRP). METHODS AND

resultsIn 27 491 initially healthy women, baseline GlycA was quantified by nuclear magnetic resonance spectroscopy and hsCRP by an immunoturbidimetric assay. During median follow-up of 17.2 years, 1648 incident CVD events occurred (myocardial infarction, ischemic stroke, coronary revascularization, and CVD death). GlycA and hsCRP were moderately correlated (Spearman r=0.61, P<0.0001). In Cox regression models that included age, ethnicity, smoking, blood pressure, medications, menopausal status, body mass index, and diabetes, hazard ratios for CVD across quartiles 1 to 4 of GlycA were 1.00, 1.10 (95% CI, 0.92 to 1.30), 1.34 (95% CI, 1.13 to 1.58), and 1.64 (95% CI, 1.39 to 1.93), similar to hsCRP, for which hazard ratios were 1.00, 1.18 (95% CI, 0.99 to 1.41), 1.35 (95% CI, 1.14 to 1.61), and 1.75 (95% CI, 1.47 to 2.09) (both Ptrend<0.0001). Associations were attenuated after additionally adjusting for lipids: the hazard ratio of quartile 4 versus 1 for GlycA was 1.23 (95% CI, 1.04 to 1.46; Ptrend=0.002) and for hsCRP was 1.44 (95% CI, 1.20 to 1.72; Ptrend<0.0001). Further adjustment for the other biomarker resulted in a hazard ratio of quartile 4 versus 1 for GlycA of 1.03 (95% CI, 0.85 to 1.24; Ptrend=0.41) and for hsCRP of 1.29 (95% CI, 1.06 to 1.56; Ptrend=0.001).

conclusionsIn this prospective study of initially healthy women, baseline GlycA was associated with incident CVD, consistent with a possible role for protein glycans in inflammation and CVD. CLINICAL TRIAL REGISTRATION URL: http//clinicaltrials.gov/. Unique identifier NCT00000479.

Indexed as

Women's HealthAgedAge DistributionBiomarkersCardiovascular DiseasesConfidence IntervalsC-Reactive ProteinDisease-Free SurvivalDouble-Blind MethodFemaleGlycosylationHumansIncidenceKaplan-Meier EstimateMagnetic Resonance SpectroscopyMiddle AgedBiomarkersC-Reactive ProteinPolysaccharidescardiovascularepidemiologyglycoproteinsinflammation

Identifiers

PMID25249300
PMCPMC4323825
OpenAlexW2104342488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.